NANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC’S Immunotherapy Workshop – Nasdaq
|
NANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC’S Immunotherapy Workshop
Nasdaq Paris, France and Cambridge, Massachusetts (USA), June 15, 2017- NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today presented new … |
Medscape |
Possible Role for Immunotherapy in Early-Stage Breast Cancer
Medscape CHICAGO — Immune checkpoint blockade may have a role in the presurgery treatment of high-risk, early-stage breast cancers, according to results from a phase 2 trial presented here at the American Society of Clinical Oncology (ASCO) 2017 Annual … |
|
Cardiac stem cells from heart disease patients may be harmful
Science Daily Patients with severe and end-stage heart failure have few treatment options available to them apart from transplants and “miraculous” stem cell therapy. But a new Tel Aviv University study finds that stem cell therapy may, in fact, harm heart disease … |
|
Targeting Immune Cells That Help Tumors Stay Hidden Could Improve Immunotherapy
Newswise (press release) Newswise — Researchers at University of Pittsburgh School of Medicine and UPMC have discovered a clue that could unlock the potential of immunotherapy drugs to successfully treat more cancers. The findings, published in Cell, were made in mice and … |
|
Stem cell therapy may harm heart disease patients, study finds
News-Medical.net Patients with severe and end-stage heart failure have few treatment options available to them apart from transplants and “miraculous” stem cell therapy. But a new Tel Aviv University study finds that stem cell therapy may, in fact, harm heart disease … |